Wednesday September 30, 2020

Amarin results boosted by €70.4m cash injection

Dublin-based clinical biopharmaceutical company Amarin has announced full-year results for 2010 which reveal that it has strengthened its balance sheet with additional $98.7 million (€70.4 million) in cash.

19th March, 2011

Dublin-based clinical biopharmaceutical company Amarin has announced full-year results for 2010 which reveal that it has strengthened its balance sheet with additional $98.7 million (€70.4 million) in cash.

The Nasdaq-listed company, which is at clinical-stage and is thus pre-revenue, said that its cash and cash equivalents balance at the end of 2010 was $31.4 million, compared to $52.3 million a year earlier.

The company booked a net loss for the year of $249.6 million last year, up from a loss...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 9 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago